Novavax NVAX Transition Services — Deferred Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:DeferredRevenue.
The source filing: Novavax’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001000694-26-000018
The Sanofi Transition Services and Sanofi Technology Transfer are recognized in revenue over time using an input method to measure progress by utilizing costs incurred to-date relative to total expected costs. Revenue recognized related to Sanofi Transition Services and Sanofi Technology Transfer for the three and six month period ended June 30, 2026 was $35.1 million and $80.5 million, respectively. Revenue recognized related to Sanofi Transition Services and Sanofi Technology Transfer for the three and six month period ended June 30, 2025 was $24.4 million and $64.7 million, respectively. The Company’s consolidated balance sheet as of June 30, 2026 includes an unbilled revenue balance of $0.9 million related to Sanofi Transition Services and Sanofi Technology Transfer. The Company recognized a cumulative catch-up adjustment related to changes in estimates, which resulted in an increase to revenue of $10.8 million and $15.4 million for the three and six month periods ended June 30, 2026, respectively. These changes in estimates resulted from changes in total expected costs and changes to estimates of variable consideration from expected cost reimbursements.
Item 1. Consolidated Financial Statements
FAQ
- What is Novavax's transition services — deferred revenue?
- Novavax (NVAX) reported transition services — deferred revenue of $900K in Q2 2026.
- How has Novavax's transition services — deferred revenue changed year-over-year?
- Novavax's transition services — deferred revenue decreased by 91.6% year-over-year, from $10.7M to $900K.
- What does transition services — deferred revenue mean?
- Deferred revenue represents payments received from customers for transition services that have not yet been earned through the delivery of performance obligations. It serves as a liability on the balance sheet that will be recognized as revenue in future periods as services are fulfilled. Monitoring this balance provides insight into the company's future revenue visibility and the pace of service delivery.
Ask your AI about Novavax's transition services — deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
